What should I do after using Ado-trastuzumab emtansine for one year?

Ado-trastuzumab emtansine is a drug used to treatHER2-positive breast cancer. After one year, patients should have further discussion and evaluation with their primary care physician to determine their next treatment plan. Doctors will evaluate whether the patient's tumor is showing signs of shrinking or stabilizing. If the disease is controlled and there is no further progression, your doctor may recommend continuing trastuzumab.

Depending on the patient's specific situation, the doctor may recommend continued use of trastuzumab or consider other treatment options such as surgery, radiation therapy, chemotherapy, etc., but this will depend on the cancer characteristics and progression of the breast cancer. Patients using trastuzumab may cause some adverse reactions, such as fatigue, nausea, abnormal liver function, etc. If these adverse effects occur, your doctor may consider adjusting the dose or looking for other treatment options. Patients should maintain close contact with their doctors before and during treatment with trastuzumab to jointly develop the most appropriate treatment plan. Patients should not adjust the drug dosage on their own to avoid force majeure side effects.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.